Back to News
Market Impact: 0.3
Novo's Sogroya Gets Positive EU Opinion For Children With Idiopathic Short Stature
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Novo Nordisk said the EMA's CHMP recommended approval of once-weekly Sogroya (somapacitan) for children with idiopathic short stature and persistent growth disorders. The positive regulatory opinion could expand Sogroya's pediatric addressable market in Europe, subject to final European Commission approval.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.40
Ticker Sentiment
NVO0.55
More News
- Apple's quarter is not perfect. But with enough to like, we raised our price target
- California’s Bay Area debates data centres ahead of US midterm elections
- ‘Fastest entertainment property in history’: GTA VI arrives to test a thin November box office
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- ‘Going hungry’: Garment workers in Bangladesh say wages barely cover needs